Herzbeteiligung bei rheumatischen Erkrankungen

C. Specker

doi:10.1055/s-0038-1636985

Arthritis und Rheuma, Inhaltsverzeichnis

Arthritis und Rheuma 2018; 38(01): 9-13
DOI: 10.1055/s-0038-1636985

Organbeteiligung bei Rheuma

Schattauer GmbH

Herzbeteiligung bei rheumatischen Erkrankungen

Heart involvement in rheumatic diseases

C. Specker

¹St. Josef-Krankenhaus/Universitätsklinikum, Essen

› Institutsangaben

Abstract

Zusammenfassung

Entzündlich-rheumatische Erkrankungen können als immunologische Systemerkrankungen in unterschiedlicher Häufigkeit auch zu einer Beteiligung des Herzens führen. Dabei können sämtliche kardialen Strukturen und Funktionen betroffen sein. Die Perikarditis beim Lupus, Mitralklappenfehler beim Antiphospholipidsyndrom, eine Myokarditis oder Coronariitis bei den systemischen Vaskulitiden sind typische Beispiele hierfür. Auch die Entwicklung einer pulmonalen arteriellen Hypertonie bei der Systemsklerose oder die Ausbildung eines kongenitalen AV-Blocks bei Neugeborenen von Müttern mit Lupus sind hierzu zu rechnen. Krankheits- und therapiebedingte kardiovaskuläre Sekundärschäden gewinnen im Langzeitverlauf dieser Erkrankungen zunehmende Bedeutung für Komorbidität und Mortalität.

Summary

Due to their systemic immunological character, inflammatory rheumatic diseases affect also the heart in varying frequency. All cardiac structures and functions can be involved. Typical examples are pericarditis in lupus, mitral valve thickening in antiphos- pholipid syndrome, myocarditis or coronariitis in systemic vasculitides. The development of pulmonary arterial hypertension in systemic sclerosis or the formation of a congenital AV block in newborns of mothers with lupus contribute also to cardiac involvement in rheumatic diseases.

Cardiovascular complications caused by damage of the disease and its therapy is becoming increasingly important for co-morbidity and mortality in the long-term course of chronic rheumatic diseases.

Schlüsselwörter

Herzbeteiligung - kardiale Komplikationen - rheumatische Erkrankungen - Arteriosklerose

Keywords

Cardiac involvement - cardiac complications - rheumatic diseases - atherosclerosis

Volltext

Referenzen

Literatur
1 Nurmohamed MT, Heslinga M, Kitas GD. Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol 2015; 11 (12) 693-704 Epub 2015 Aug 18.
2 Avina-Zubieta JA, Choi HK, Sadatsafavi M. et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a metaanalysis of observational studies. Arthritis Rheum 2008; 59: 1690-1697.
3 Roubille C, Richter V, Starnino T. et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015; 74: 480-489.
4 Jung H, Bobba R, Su J. et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 2010; 62 (03) 863-868.
5 Solomon DH, Liu CC, Kuo IH. et al. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis 2016; 75 (09) 1674-1679.
6 Braun J, Krüger K, Manger B. et al. Kardiovaskuläre Komorbiditäten bei entzündlich-rheumatischen Erkrankungen. Dtsch Arztebl Int 2017; 114 (12) 197-203.
7 Gordis L. The virtual disappearance of rheumatic fever in the United States: Lessons in the rise and fall of disease. Circulation 1985; 72: 1155-1162.
8 van der Helm-van Mil AH. Acute rheumatic fever and poststreptococcal reactive arthritis reconsidered. Current opinion in rheumatology 2010; 22 (04) 437-442.
9 Goodsona NJ, Solomon DH. The cardiovascular manifestations of rheumatic diseases. Curr Opin Rheumatol 2006; 18: 135-140.
10 Corrao S, Messina S, Pistone G. et al. Heart involvement in rheumatoid arthritis: systematic review and meta-analysis. Int J Cardiol 2013; 167 (05) 2031-2038.
11 Lange U, Strunk J. Kardiovaskuläre Manifestationen bei entzündlich-rheumatischen Erkrankungen. Z Rheumatol 2005; 64: 12-17.
12 Kobayashi Y, Giles JT, Hirano M. et al. Assessment of myocardial abnormalities in rheumatoid arthritis using a comprehensive cardiac magnetic resonance approach: a pilot study. Arthritis Research & Therapy 2010; 12 (05) R171.
13 Movahedian M, Afzal W, Shoja T. et al. Chest Pain Due to Pericardial Effusion as Initial Presenting Feature of Rheumatoid Arthritis: Case Report and Review of the Literature. Cardiol Res 2017; 08 (04) 161-164.
14 Lautermann D, Braun J. (2002) Ankylosing spondylitis – cardiac manifestations. Clinical and experimental rheumatology 2002; 06 (Suppl. 28) 11-15.
15 Tselios K, Urowitz MB. Cardiovascular and Pulmonary Manifestations of Systemic Lupus Erythematosus. Curr Rheumatol Rev 2017; 13 (03) 206-218.
16 Chen J, Tang Y, Zhu M, Xu A. Heart involvement in systemic lupus erythematosus: a systemic review and meta-analysis. Clin Rheumatol 2016; 35 (10) 2437-2448.
17 Cauduro SA, Moder KG, Tsang TS, Seward JB. Clinical and echocardiographic characteristics of hemodynamically significant pericardial effusions in patients with systemic lupus erythematosus. Am J Cardiol 2003; 92: 1370-1372.
18 Harris EN, Chan JKH, Asherson RA. et al. Thrombosis, recurrent fetal loss and Thrombocytopenia. Arch Intern Med 1986; 146: 2153-2156.
19 Hojnik M, George J, Ziporen L, Shoenfeld Y. Heart Valve Involvement (Libman-Sacks Endocarditis) in the Antiphospholipid Syndrome. Circulation 1996; 93: 1579-1587.
20 Specker C, Rademacher J, Sohngen D. et al. Cerebral microemboli in patients with antiphospholipid syndrome. Lupus 1997; 06: 638-644.
21 Asherson RA, Harris EN, Gharavi AE, Hughes GRV. Myocardial infarction in SLE and “lupuslike” disease. Arthritis Rheum 1986; 29: 1292-1293.
22 Hahn BH. Systemic lupus erythematosus and accelerated atherosclerosis. N Engl J Med 2003; 349: 2379-2380.
23 Petri M, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine 1992; 71: 291-302.
24 Specker C, Fischer-Betz R. Gynäkologische und geburtshilfliche Probleme beim Sjögren-Syndrom. Akt Rheumatol 2005; 30: 56-58.
25 Salomonsson S, Sonesson SE, Ottosson L. et al. Ro/ SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block. J Exp Med 2005; 201: 11-17.
26 Brucato A, Frassi M, Franceschini F. et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum 2001; 44 (08) 1832-1835.
27 Buyon JP, Hiebert R, Copel J. et al. Autoimmuneassociated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 1998; 31: 1658-1666.
28 Izmirly PM, Saxena A, Kim MY. et al. Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti- SSA/Ro-associated cardiac neonatal lupus. Circulation 2011; 124 (18) 1927-1935.
29 Levesque K, Morel N, Maltret A. et al. “Lupus néonatal” group; Group of collaborators. Description of 214 cases of autoimmune congenital heart block: Results of the French neonatal lupus syndrome. Autoimmun Rev 2015; 14 (12) 1154-1160.
30 Saxena A, Izmirly PM, Mendez B. et al. Prevention and treatment in utero of autoimmune-associated congenital heart block. Cardiol Rev 2014; 22 (06) 263-267.
31 Ferri C, Valentini G, Cozzi F. et al. Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSSSc). Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002; 81 (02) 139-153.
32 Elhai M, Meune C, Boubaya M. et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis 2017; 76 (11) 1897-1905.
33 Gladue H, Altorok N, Townsend W. et al. Screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension: a systematic review. Semin Arthritis Rheum 2014; 43 (04) 536-541.
34 Jennette JC, Falk RJ, Bacon PA. et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of vasculitides. Arthritis Rheum 2013; 65: 1-11.
35 Pagnoux C, Guillevin L. Cardiac involvement in small and medium-sized vessel vasculitides. Lupus 2005; 14 (09) 718-722.
36 Knockaert DC. Cardiac involvement in systemic inflammatory diseases. Eur Heart J 2007; 28 (15) 1797-1804.
37 Misra DP, Shenoy SN. Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk. Rheumatol Int. 2016 Feb 17. [Epub ahead of print].